Why the study?
During 2017 several landmark studies were published with practical implications for ASCVD prevention and risk factor control, including lipids and lipoproteins, inflammation, diabetes, hypertension, and healthy lifestyle, on top of optimal medical therapy.
This 2017 year-in-review summarizes landmark evidence demonstrating that novel therapies (such as PCSK9 inhibitors, anti-inflammatory agents, and low-dose factor Xa antagonism) and lifestyle factors significantly impact residual cardiovascular risk on top of optimal medical therapy.
Tijekom 2017.objavljeni su rezultati nekoliko studija koje imaju praktične implikacije za prevenciju i kontrolu čimbenika rizika od aterosklerotske kardiovaskularne bolesti (ATSKVB), poput lipida, lipoproteina, upale, šećerne bolesti, arterijske hipertenzije i zdravog stila života.Izabrali smo izraz ATSKVB kako bismo pojednostavnili čitanje članka za nespecijaliste, iako moramo napomenuti da se točna dijagnoza ATSKVB-a ponešto razlikuje od studije do studije.Napominjemo da u dijelu gdje se ATSKVB ne može smatrati relevantnim čimbenikom ishoda (npr.istraživanja u arterijskoj hipertenziji), ne koristimo se izrazom ATSKVB, nego rabimo izraze za čimbenike ishoda specifične pojedinom području.Sve relevantne studije provedene su uz optimalnu farmakološku terapiju, prema postojećim Smjernicama Europskog kardiološkog društva (ESC) i Europskog društva za aterosklerozu (EAS) za prevenciju ATSKVB i liječenje dislipidemija.1,2 Primjerice, u okrilju novih znanstvenih dokaza o dodatnom preamble During 2017 several landmark studies have been published that have practical implications for atherosclerotic cardiovascular disease (ASCVD) prevention and risk factor control, such as lipids and lipoproteins, inflammation, diabetes, hypertension, and healthy lifestyle.We use the term 'ASCVD' where relevant to simplify the reading of this article for the non-specialist, although the exact definition as ASCVD differ slightly from study to study.However, in sections where AS-CVD clearly is not the relevant endpoint (e.g. in hypertension research) we do not use 'ASCVD', but instead of use other words to describe endpoints.All relevant trials have been performed on a background of optimal medical therapy, such as described in the European Society of Cardiology(ESC)/European Atherosclerosis Society (EAS) guidelines on ASCVD prevention and management of dyslipidaemia for lipid-lowering.1,2 For example, important new evidence for
No takes yet. Share an insight, caveat, or question.
Nordestgaard et al. (2018) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolaemia. ASCVD prevention strategies (PCSK9 inhibition, CETP inhibition, interleukin-1β inhibition, low-dose factor Xa antagonism, statins, and lifestyle modifications) was evaluated on Atherosclerotic cardiovascular disease (ASCVD) events and risk factor control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: